GET DAILY SIGNALSKalaris Therapeutics (KLRS): Analyst Targets Point to Roughly +700% Upside Potential
Key Takeaways
- The central $16 stock price target is the arithmetic mean of five verified analyst price targets, rounded from $16.40; the individual targets span a wide range of roughly $7 to $25.
- With shares trading near $2.00, reaching $16 would require an upside of roughly 700% — a very large move by any conventional measure.
- Kalaris Therapeutics, Inc. (KLRS) is a pre-revenue, clinical-stage biopharmaceutical company developing TH103 for neovascular (wet) age-related macular degeneration (AMD).
- The strongest supporting factor is TH103's early clinical data, which showed functional and structural improvements plus potential durability in wet AMD, a large anti-VEGF market.
- The biggest risks are the absence of revenue, ongoing cash burn, heavy share dilution, and the binary nature of clinical development in a competitive AMD market.
- You can explore more about the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
- Explore Trending AI Robots for additional market insight and automated monitoring tools.
Analyst Price Targets and the Consensus View
Kalaris Therapeutics is covered by a small group of Wall Street firms, and their targets are unusually dispersed. Verified individual price targets include Piper Sandler at $7 (Hold, March 2026), Morgan Stanley at $14 (Overweight, initiated April 2026 and reiterated August 2026), Wedbush at $17 (Outperform, initiated May 2026 and maintained), Chardan Capital at $19 (Buy, December 2025), and Citizens JMP at $25 (Outperform, May 2026). Averaging these five targets produces a mean of $16.40, which rounds to the $16 central target used here. Independent aggregators report slightly different consensus figures — roughly $15.50 to $18.75 — reflecting different analyst sets and timestamps rather than disagreement over direction.
An important caveat applies: most of these targets were set between December 2025 and August 2026, before the stock's sharp decline. As a result, the analyst price target range reflects a pre-decline view and may not yet have "caught up" to the current price. The bull case centers on TH103's differentiation and durability; the cautious case, represented by the lone Hold rating, reflects financing and clinical-execution risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and the Path Toward the Target
Shares of KLRS trade near $2.00, within a 52-week range of roughly $1.78 to $11.88 and down about 58% to 60% over the past year. Reaching the $16 central target would require a gain of about 700% — a very large move. The company is pre-revenue, with roughly $93 million in cash, minimal debt, and a market capitalization near $46 million to $48 million. Because the stock is driven almost entirely by clinical catalysts rather than fundamentals such as earnings or revenue, its path toward any higher level depends on positive data readouts and renewed financing confidence rather than incremental operating progress.
What Could Support a Move Toward the Target
The central investment thesis is TH103, Kalaris's candidate for wet AMD. Expanded Phase 1a results showed encouraging efficacy signals, including functional and structural improvements and the potential for longer treatment durability, which analysts view as a possible differentiator in the roughly $15 billion anti-VEGF market. Upcoming Phase 1b/2 multiple-dose data, expected in the first half of 2027, is the key catalyst. A clean balance sheet with substantial cash and low leverage also supports the company's ability to fund development, and recent strengthening of its financial leadership has been cited as a positive for future capital access.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Kalaris generates no revenue, and its negative cash generation means it must continue raising capital while programs remain in development. The share count has increased more than 40% year over year, and a December 2025 private placement plus an at-the-market offering of up to $100 million create ongoing dilution risk. Shrinking shareholders' equity reflects cumulative losses, and the wet-AMD space is crowded with established therapies, meaning TH103 must demonstrate clear differentiation to justify commercial value. Any clinical setback, safety concern, or financing difficulty could weigh heavily on a pre-revenue biotech with a small float.
Technical Levels and Market Structure
The stock trades well below both its 50-day moving average (near $2.63) and 200-day moving average (near $5.10), indicating a persistent downtrend. The 52-week low near $1.78 is the nearest support level to watch, while the former range in the $4 to $5 area represents overhead resistance. A sustained move toward the analyst-derived target would first require reclaiming these moving averages and the psychologically important $5 level, a substantial technical recovery from current prices. From what I see, these levels remain important markers for any potential recovery.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though the actual horizon varies by firm and most of these targets predate the recent decline. The single most important upcoming item is the Phase 1b/2 multiple-dose data for TH103 expected in the first half of 2027. Investors should also monitor quarterly cash balances and burn rates, any new financing or dilution announcements, analyst target revisions following the data, and sector-wide sentiment toward clinical-stage biotech and anti-VEGF therapies. No specific timing for reaching any target can be assumed. I’m watching this closely as the data readout approaches.
Final Assessment
The $16 central target for Kalaris Therapeutics is the arithmetic mean of five verified analyst targets spanning roughly $7 to $25, and it sits about 700% above the current price — a very large, low-probability near-term move that depends almost entirely on clinical success. The bull case rests on TH103's early efficacy and durability signals in a large wet-AMD market, supported by a healthy cash position. The bear case rests on zero revenue, persistent cash burn, heavy dilution, and a stock mired in a downtrend below all major moving averages. With Phase 1b/2 data not expected until the first half of 2027, the gap between the current price and the analyst-derived target is best understood as a reflection of pre-decline optimism rather than a near-term forecast. Investors should watch the data readout, cash runway, and financing decisions as the decisive variables.
Using AI Tools to Track Momentum
In my own analysis, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor volatile, catalyst-driven names like this one. The tool uses artificial intelligence to scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on market conditions and technical behavior. It helps me spot shifts in momentum more efficiently alongside my fundamental work, especially when clinical timelines stretch out. This approach keeps me alert to changing trends without replacing my own research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KLRS's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for KLRS moved into oversold territory on November 11, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KLRS's RSI Oscillator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for KLRS just turned positive on October 28, 2026. Looking at past instances where KLRS's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +19.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where KLRS advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KLRS as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KLRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KLRS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KLRS entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.999) is normal, around the industry mean (3.498). P/E Ratio (-1.277) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. KLRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KLRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology